Public Release: 

Preclinical drug developed to prevent gastrointestinal side effects of type 1 diabetes

Cell Press

Up to 80% of individuals living with long-term type 1 diabetes experience gastrointestinal symptoms such as abdominal distension, irritable bowel syndrome, and fecal incontinence. A study publishing October 1 in Cell Stem Cell reveals why these symptoms arise and tests an investigational drug in mice that could prevent them from developing.

It's unclear why diabetic patients often experience gastrointestinal symptoms, collectively known as diabetic enteropathy, and there currently are no therapies that patients can take to prevent their onset. Studies in diabetic rodents suggest that diabetes may alter the intestine's mucosal lining, which is maintained and regenerated by intestinal stem cells; however, little is known about how this occurs and whether it is relevant to humans.

Researchers from Boston Children's Hospital and Harvard Medical School in Boston and from San Raffaele Hospital in Milan, Italy led by Dr. Paolo Fiorina investigated the issue by examining intestinal tissues from diabetic patients and healthy individuals. The team found that individuals with long-standing type 1 diabetes and diabetic enteropathy have altered colonic stem cells (CoSCs) and increased blood levels of a regulatory protein called insulin-like growth factor binding protein 3 (IGFBP3), which is produced in the liver. Additional experiments revealed that IGFBP3 has a toxic effect on CoSCs and the structure of the intestine's mucosal lining.

"A potential new treatment for diabetic enteropathy might reduce the level of IGFBP3 by preventing its production and release from the liver; however, interfering with liver function is somewhat problematic and potentially dangerous," says Dr. Fiorina. "That is why we decided to create a new drug capable of quenching free circulating IGFBP3."

When injected into mice, the researchers' investigational drug, which traps IGFBP3, prevented the onset of gastrointestinal symptoms and restored the full function and structure of the intestine's mucosal lining. "The next challenge really is to create a clinical grade compound," says Dr. Fiorina. "The blueprint has been already established."


This research was supported by the American Diabetes Association, the Italian Scientists and Scholars of North America Foundation, the Minister of Health of Italy, the EFSD/Sanofi European Research Programme, the American Heart Association, the American Society of Transplantation, and FAPESP, CNPq.

Cell Stem Cell, D'Addio and La Rosa et al.: "Circulating IGF-I and IGFBP3 Levels Control Human Colonic Stem Cell Function and Are Disrupted in Diabetic Enteropathy"

Cell Stem Cell (@CellStemCell), published by Cell Press, is a monthly journal that publishes research reports describing novel results of unusual significance in all areas of stem cell research. Each issue also contains a wide variety of review and analysis articles covering topics relevant to stem cell research ranging from basic biological advances to ethical, policy, and funding issues. For more information, please visit To receive media alerts for this or other Cell Press journals, contact

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.